Biotech Values

[10nisman]

MON

<< But I think we will get a couple more opportunities this year to accumulate additional shares at $65-68 for the longer term story. >>

Based on MON's new earnings guidance I wouldn't be surprised if it traded in the low $60's (maybe even high $50's) sometime over the next 9-12 months, as it trades more in line with the general market. IMO, the $100 MS analyst target price is just insane unless its the analyst's estimated take-over price or estimated target price for 2013/2014.

10nis